Oncopeptides AB (publ) (OM: ONCO)
Health Care · Biotechnology · SE
Skr1.68
+6.21% today · -62.6% 1Y
Oncopeptides AB (publ) (OM: ONCO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $69.96M and employs 77 people.
Over the last twelve months the share price has lost 62.6%, trading between 1.26 and 6.55.
Tweenvest scores Oncopeptides AB (publ) across four factors: quality 25/100, value 79/100. Its strongest factor is value.
ONCO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $69.96M
- Revenue (TTM)
- $8.75M
- P/E
- —
- EPS
- -0.91
- Dividend yield
- —
- Beta (5Y)
- -1.33
- 52-week high
- Skr6.55
- 52-week low
- Skr1.26
- Avg volume (3M)
- —
- Shares outstanding
- 395.29M
- Employees
- 77
- Next earnings
- —
About Oncopeptides AB (publ)
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
- ISIN
- SE0009414576
- Founded
- 2000
- Listed since
- Feb 22, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.